BTIG Reiterates Buy on Rapport Therapeutics, Maintains $53 Price Target

Benzinga Newsdesk www.benzinga.com Neutral 88.8%

Neg 0% Neu 88.8% Pos 0%

BTIG analyst Kambiz Yazdi reiterates Rapport Therapeutics (NASDAQ:RAPP) with a Buy and maintains $53 price target.

Comments

No comments yet. Be the first!